SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for alleged violations of securities laws, specifically related to misleading statements about its drug candidate, nimacimab, and its commercial prospects [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to investors who purchased Skye's securities between November 4, 2024, and October 3, 2025, and encourages them to contact the Schall Law Firm before January 16, 2026 [2]. - The complaint alleges that Skye made false and misleading statements regarding the effectiveness of nimacimab and overstated its commercial and clinical prospects [4]. Group 2: Investor Impact - Investors suffered damages when the truth about Skye's drug candidate and its market position was revealed [4]. - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [4].